PFS. (A) PFS among all patients; (B) PFS among patients with unmutated IGHV; (C) PFS among patients with mutated IGHV; (D) PFS for patients remaining on ibrutinib. Patients who went off ibrutinib for AEs or reasons other than progression are censored at the time of ibrutinib discontinuation.